Archives
M-A: No difference in outcomes with Beta-lactam monotherapy vs. combination therapy for bloodstream infections or pneumonia due to P. aeruginosa.
21 Jan, 2022 | 09:37h | UTCBeta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to P. aeruginosa: a meta-analysis – International Journal of Antimicrobial Agents (link to abstract – $ for full-text)
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
21 Jan, 2022 | 09:31h | UTCThe validity of progression-free survival 2 as a surrogate trial end point for overall survival – Cancer (link to abstract – $ for full-text)
M-A: In patients with acute coronary syndrome, a guided approach (i.e., platelet function or genetic testing) to P2Y12 inhibiting therapy may reduce major adverse cardiovascular events without increased risk of bleeding.
21 Jan, 2022 | 09:33h | UTCComparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials – European Heart Journal (link to abstract – $ for full-text)
Commentary: Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis – TCTMD
Commentary on Twitter
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials: read more in EHJ!https://t.co/oAehSfPVdt#cardiotwitter @ESC_Journals @escardio pic.twitter.com/AEuH7V6IkR
— EHJ Editor-in-Chief (@ehj_ed) December 23, 2021
RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.
21 Jan, 2022 | 09:28h | UTCPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
M-A: In comatose survivors of cardiac arrest, targeted hypothermia is not associated with improved survival or better neurological outcomes vs. targeted normothermia.
21 Jan, 2022 | 09:29h | UTCRelated:
Systematic Review: Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis.
21 Jan, 2022 | 09:24h | UTC
Consensus statements for the assessment and management of non-radiographic axial spondyloarthritis.
21 Jan, 2022 | 09:26h | UTC
Cluster Randomized Trial: A multifactorial falls prevention program in UK care homes reduced fall rates among older people and was cost effective.
21 Jan, 2022 | 09:21h | UTCNews Release: Falls in care homes can be significantly reduced with intervention, says new study – University of Nottingham
Commentary on Twitter
NEW RESEARCH: A falls prevention programme for older people in care homes, co-designed with care home staff & residents, that involved awareness raising, education, screening, decision & implementation support was associated with a reduction in falls rate https://t.co/wupI0LeAxj
— The BMJ (@bmj_latest) December 11, 2021
Booster longevity: Data reveals how long a third shot protects.
20 Jan, 2022 | 09:33h | UTCBooster longevity: Data reveals how long a third shot protects – NPR
Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency
An updated overview of low back pain management.
21 Jan, 2022 | 09:23h | UTCAn Updated Overview of Low Back Pain Management – Asian Spine Journal
A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.
20 Jan, 2022 | 09:30h | UTCEffectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine
Commentary on Twitter
In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW
— NEJM (@NEJM) January 19, 2022
RCT: Lidocaine spray may reduce pain during radial arterial puncture.
21 Jan, 2022 | 09:19h | UTCEffectiveness of lidocaine spray on radial arterial puncture pain: A randomized double-blind placebo controlled trial – The American Journal of Emergency Medicine (link to abstract – $ for full-text)
Heart function recovered quickly in children with COVID-19-related multisystem inflammatory syndrome (MIS-C).
20 Jan, 2022 | 09:26h | UTCNews Release: Heart function recovered quickly in children with COVID-19-related MIS-C condition – American Heart Association
Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.
20 Jan, 2022 | 09:25h | UTCFluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal
Related:
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Milder disease with Omicron: is it the virus or the pre-existing immunity?
20 Jan, 2022 | 09:28h | UTC
How does Omicron spread so fast? A high viral load isn’t the answer – “Data on viral levels point to immune evasion as a cause of the variant’s transmissibility”.
20 Jan, 2022 | 09:27h | UTCHow does Omicron spread so fast? A high viral load isn’t the answer – Nature
A large observational study showed people with immune disfunction (HIV, solid organ transplant, rheumatoid arthritis) were at increased risk of breakthrough Covid-19 infection after vaccination.
20 Jan, 2022 | 09:24h | UTC
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
20 Jan, 2022 | 09:17h | UTCGlobal burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet
Editorial: Antimicrobial resistance: time to repurpose the Global Fund – The Lancet
Commentary: Antimicrobial resistance now a leading cause of death worldwide, study finds – The Guardian
Commentary on Twitter
NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria.#GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: https://t.co/2h5UEKemEq #AMRSOS pic.twitter.com/aWLhmdirJ8
— The Lancet (@TheLancet) January 20, 2022
10 lessons I’ve learned from the Covid–19 pandemic.
20 Jan, 2022 | 09:21h | UTC10 lessons I’ve learned from the Covid–19 pandemic – STAT
Covid pandemic ‘nowhere near over,’ WHO says.
20 Jan, 2022 | 09:18h | UTCCovid pandemic ‘nowhere near over,’ WHO says – CNN
After Omicron, we could use a break. We may just get it.
20 Jan, 2022 | 09:21h | UTCAfter Omicron, we could use a break. We may just get it – STAT
RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).
20 Jan, 2022 | 09:11h | UTCSER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection – New England Journal of Medicine (link to abstract – $ for full-text)
1.8 million excess deaths attributable to urban air pollution in 2019, modelling study suggests.
20 Jan, 2022 | 09:13h | UTCNews Release: The Lancet Planetary Health: 1.8 million excess deaths attributable to urban air pollution in 2019, modelling study suggests
Related Studies:
Commentary on Twitter (thread – click for more)
NEW—Approx. 86% of people living in urban areas exposed to unhealthy particulate matter levels, leading to 1.8 million excess deaths in 2019: modelling study in @TheLancetPlanet. #AirPollutionhttps://t.co/kw34ANZ4ph
Thread 🧵 pic.twitter.com/QiRXU4QVHP
— The Lancet (@TheLancet) January 6, 2022
RCT: In very young children with Type 1 Diabetes, a hybrid closed-loop therapy (“artificial pancreas”) resulted in better glycemic control without increased risk of hypoglycemia vs. sensor-augmented pump therapy.
20 Jan, 2022 | 09:07h | UTCRandomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
M-A: the accuracy of serological tests to support the diagnosis of celiac disease.
20 Jan, 2022 | 09:02h | UTC